Mylan vs. FDA (And Ranbaxy): Diovan Exclusivity Forfeiture Edition
This article was originally published in The Pink Sheet Daily
Executive Summary
In a suit against FDA, Mylan argues that Ranbaxy’s delay in getting tentative approval for its valsartan ANDA within 30 months of submission triggered forfeiture of its 180-day marketing exclusivity.
You may also be interested in...
Ranbaxy’s Valsartan ANDA Wins FDA Approval After Lengthy Delay
Regulatory nod gives Ranbaxy green light to launch its generic version of Novartis’ Diovan with 180-day exclusivity; other ANDA holders may continue to challenge Ranbaxy’s hold on the market.
Teva Claims Diovan 180-Day Exclusivity, Arguing Ranbaxy ANDA Was Incomplete
Teva supports citizen petition claiming Ranbaxy is ineligible for exclusivity but says that it is the actual first ANDA filer; generic has yet to launch nearly two years after Novartis’ Diovan patents expired.
Teva Claims Diovan 180-Day Exclusivity, Arguing Ranbaxy ANDA Was Incomplete
Teva supports citizen petition claiming Ranbaxy is ineligible for exclusivity but says that it is the actual first ANDA filer; generic has yet to launch nearly two years after Novartis’ Diovan patents expired.